Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the upcoming Guggenheim Healthcare Innovation Conference in Boston.
Stocks · News reference
Helus Pharma Provides Clinical Program Updates for HLP003 and HLP004
Helus Pharma announced that its HLP003 Phase 3 study for major depressive disorder remains on track for a Q4 2026 data readout, while its HLP004 Phase 2 study for generalized anxiety disorder is expected to begin in Q1 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Insider Cluster Buying Reported at Helus Pharma Inc.
Four insiders at Helus Pharma Inc. have collectively purchased approximately $9.67 million in company stock.
Helus Pharma Announces Co-Founders' Transition from Executive Leadership
Helus Pharma co-founders Eric So and Paul Glavine have stepped down from their executive and consulting roles, while Mark Lawson has been appointed as the new independent Chair of the Board of Directors.
Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22
Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"),
Helus Pharma shares are trading higher after the company announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026.